Novavax Stock News

Novavax stock is under pressure on litigation and competition headwinds. Is NVAX stock a buy or a sell today?

Is Novavax stock a buy after vaccine stocks surged on bullish news from Moderna? Is NVAX stock a buy right now?

Novavax stock is on the downswing again after the company cut its outlook for the year. Is NVAX stock a buy or a sell right now?

Novavax stock jumped this month as the company launched its updated Covid shot abroad. Is NVAX stock a buy or a sell right now?

In the most recent trading session, Novavax (NVAX) closed at $14.06, indicating a +1.99% shift from the previous trading day.

It was not long ago that Novavax (NASDAQ: NVAX ) was among the stocks with high short interest. The stock had been trending lower for an extended period.

Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.

Novavax has seen a surge in stock price due to recent COVID-19 and bird flu vaccine developments, reaching over $27 per share. The company is making headlines with updates on their COVID-19 vaccine, b

Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax's JN.1 COVID-19 vaccine would be the only protein-based option available in the U

Novavax's stock is highly volatile due to the company's instability and inconsistent financial results. Sanofi has partnered with the company, and that has sparked a wave of excitement in Novavax's st

Penny stocks have the tendency to surprise when it comes to delivering stellar returns at the blink of an eye. A good example is Novavax (NASDAQ: NVAX ) that has delivered 203% returns for year-to-dat

With the ongoing GameStop saga reigniting interest in meme stocks, investors, or more likely traders and speculators, are once again seeking out stocks with high short interest. As the overall market,

On Friday, the U.S. Federal Drug Administration (FDA) okayed the launch of updated vaccines as part of the 2024-2025 campaign against new Covid strains.  Drug manufacturers have been waiting on appro

The S&P 500 has hit more than one record high this year, and technology stocks have led the gains. It's a great idea to get in on stocks that have remained in the doldrums but could have a bright futu

Last week, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.